Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
Morales DR, Conover MM, You SC, Pratt N, Kostka K, Duarte-Salles T, Fernández-Bertolín S, Aragón M, DuVall SL, Lynch K, Falconer T, van Bochove K, Sung C, Matheny ME, Lambert CG, Nyberg F, Alshammari TM, Williams AE, Park RW, Weaver J, Sena AG, Schuemie MJ, Rijnbeek PR, Williams RD, Lane JCE, Prats-Uribe A, Zhang L, Areia C, Krumholz HM, Prieto-Alhambra D, Ryan PB, Hripcsak G, Suchard MA. Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. The Lancet Digital Health 2020, 3: e98-e114. PMID: 33342753, PMCID: PMC7834915, DOI: 10.1016/s2589-7500(20)30289-2.Peer-Reviewed Original ResearchAngiotensin receptor blockersCalcium channel blockersAcute respiratory distress syndromeAcute kidney injuryHospital admissionRespiratory distress syndromeCOVID-19 diagnosisKidney injuryDistress syndromeDrug classesCohort analysisCOVID-19Renin-angiotensin system blockersThiazide-like diureticsBaseline patient characteristicsUse of ACEIsPost-authorisation studiesUK National InstituteRelative risk differenceNational InstituteCombination useMedical Research CouncilAustralian National HealthElectronic health recordsAntihypertensive users